Catalyst
Slingshot members are tracking this event:
Aerie (AERI) Reports 12 Month Safety Data from Phase 3 ROCKET-2 Study Evaluating Rhopressa in Lowering Intraocular Pressure in Patients with Glaucoma or Ocular Hypertension
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| AERI |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Mar 17, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
12 Month Safety Data, Rhopressa, Phase 3 Rocket-2, Lowering Intraocular Pressure, Glaucoma, Ocular Hypertension
